(Observer Network News) China's Sinovac vaccine, which was administered on a large scale in , Indonesia, , has received good news: for 25,000 medical staff with high infection risk, the effective rate of infection prevention is 94%, and the prevention rate of infection death is 100%. Effect. Indonesia's health minister said the Sinovac vaccine had "dramatically reduced" hospitalizations and deaths among healthcare workers.
Kexing's chairman Yin Weidong said that more and more evidence proves that Kexing's vaccine is more effective in actual use than in clinical trials. The US Bloomberg commented that this data is good news for many developing countries, and to a certain extent counters criticisms about the validity of China's vaccine data.
Bloomberg: China's Kexing vaccine is seen as highly effective in real-world research. A follow-up investigation by a medical staff found that within 28 days after was vaccinated with with two doses of Kexing vaccine, the effective rate of in preventing new coronary pneumonia infection reached 94%, the infection mortality prevention rate was 100%, and cases were hospitalized 7 days after inoculation The prevention rate is 96%.
"(After the Sinovac vaccine) we saw a dramatic drop in hospitalization and mortality among medical staff," he said.
Currently, Indonesia is still the most severely affected country in Southeast Asia, with more than 1.72 million confirmed cases and 47,465 deaths. Sadikin did not mention the specific efficacy of the vaccine against each strain of the new coronavirus. However, there has not been a large-scale mutation virus infection in Indonesia recently.
As early as January this year, Indonesia signed an agreement to purchase Sinovac vaccines. As of early April, about 56 million doses of Sinovac vaccines have been obtained.According to local media statistics, as of May 4, more than 20 million people in Indonesia have received at least one dose of the vaccine, accounting for 4.64% of the total population, most of which are Kexing vaccines. Indonesia plans to complete the vaccination of 181.5 million people within this year and achieve herd immunity .
In February this year, medical staff in South Sulawesi, Indonesia were vaccinated with the Sinovac vaccine Photo from: The Paper
Bloomberg commented that Sinovac vaccine is "eliminating" the infection among Indonesian medical staff, and the 94% protection rate data is "extremely excellent" (extraordinary) , which is better than the results of Phase III clinical trials conducted by Sinovac in various places.
On April 11 this year, the final results of the Phase III clinical trial of Sinovac announced by Brazilian Butantan Institute showed that the vaccine has a protective efficacy of 50.7% in preventing all new crown cases in an environment with a higher virus exposure rate. The protective efficacy of severe and severe disease was 83.7% and 100%, respectively. All serious adverse reactions turned out to be unrelated to the vaccine.
On April 16, the effectiveness report released by Chile also mentioned that 14 days after inoculation with two doses of Sinovac vaccine, the effective rate of preventing new coronary pneumonia infection was 67%, the prevention rate of hospitalized cases was 85%, and the prevention rate of severe cases was 89%. , the infection mortality prevention rate was 80%. The World Health Organization Strategic Advisory Group of Experts on Immunization assessed "high confidence" in the effectiveness of two doses of Sinovac vaccine.
Indonesian President Joko Widodo's live broadcast of the Kexing vaccine video screenshot
The data from Brazil has become an excuse for many western media to wear tinted glasses and attack China's vaccines with relatively low effectiveness. This article by Bloomberg is no exception, and still labels the Sinovac vaccine as "full of controversy" and "far less effective than Western vaccines".
On the 11th local time, Sinovac chairman Yin Weidong said in an interview with Bloomberg that more and more evidence has proved that Sinovac vaccines are more effective in actual use than in clinical trials. According to US media reports in early May, a small town of 45,000 people in Brazil received the Sinovac vaccine, the infection rate dropped by 75%, and the infection death prevention rate reached 100%. strain is effective.
Yin Weidong said that due to the existence of mutated viruses, the protection rate data of Sinovac vaccines may vary from place to place. But around the concerns of dealing with mutated viruses, the Sinovac vaccine has clearly "stood up".
Helen Petousis-Harris, associate professor of virology at the University of Auckland, said it was true that vaccines could be more effective in practice than clinical trials showed. "In my personal experience, we often cannot predict the full impact of vaccines, and we can only understand them after large-scale use in reality." She also emphasized that mass vaccination can not only save lives, but also reduce the chance of mutated viruses appearing.
Bloomberg acknowledged that there is growing evidence that Sinovac's vaccine has strongly underpinned China's efforts to provide vaccines to developing countries. The data from Indonesia is encouraging news for many developing countries and partly counters criticism of the validity of China's vaccine data.
This article is an exclusive manuscript of Observer.com and may not be reproduced without authorization.
